The use of a c-Met inhibitor or a p-Smad2 inhibitor in combination with a HER2 inhibitor might be promising against lymph node metastasis in patients with HER2-positive gastric cancer. The gene discussed is MET; the disease is metastatic malignant neoplasm in the lymph nodes.